Content Type: Article

  • Broker-Dealers: B-Ds Receive Consolidated Audit Trail (“CAT”) Relief Due to COVID-19 Pandemic

    Broker-Dealers: B-Ds Receive Consolidated Audit Trail (“CAT”) Relief Due to COVID-19 Pandemic

    ARTICLE / CLIENT ALERT

    Broker-Dealers: B-Ds Receive Consolidated Audit Trail (“CAT”) Relief Due to COVID-19 Pandemic

    March 18, 2020

    Read time: 6 min

    Key takeaways
    Overview

    In light of public health issues caused by the outbreak of coronavirus disease 2019 (“COVID-19”), on March 16, 2020, the staff of the Division of Trading and Markets of the U.S. Securities and Exchange Commission provided no-action relief to the self-regulatory organizations (“SROs”) responsible for ensuring compliance with the National Market System Plan governing the Consolidated Audit Trail (“CAT NMS Plan”).[1] Following this announcement, the Operating Committee for the CAT NMS Plan announced that it understood that these SROs would not take disciplinary action against their members for failing to commence reporting to the Consolidated Audit Trail (“CAT”) prior to May 20, 2020.[2]

    Background

    The CAT is a central repository that will receive, consolidate and retain the trade and order lifecycle data for all NMS securities (i.e., listed equities and options) and over-the-counter (“OTC”) equity securities. Under the CAT NMS Plan and related self-regulatory organization rules, exchanges, other SROs and broker-dealers will be required to submit order lifecycle information to the CAT for each trading day on a nightly basis. CAT requirements are applicable to all U.S. exchanges and broker-dealers and — unlike existing trade reporting utilities (e.g., FINRA’s Order Audit Trail System (“OATS”)) — no U.S. broker-dealers are exempt from CAT requirements.[3]

    No-Action Relief

    Broker-dealers have a number of upcoming CAT compliance dates that are separated into multiple phases (“Phased Reporting”) through 2022. Under the Phased Reporting[4] plan, broker-dealers (other than small broker-dealers) (“Large Broker-Dealers”) and small broker-dealers[5] (“Small Broker-Dealers”) would have been required to submit member data[6] to the CAT by April 20, 2020.[7] The no-action relief provides that the staff will not recommend enforcement action against SROs under Section 19(g)(1) of the Exchange Act and Rule 608(c) of Regulation NMS should the SROs not enforce the CAT NMS Plan implementation dates. The SEC no-action relief extends until May 20, 2020, unless it is extended. Immediately following the release of the SEC no-action letter, the Operating Committee for the CAT NMS Plan announced that, consistent with this relief, the SROs responsible for enforcing the CAT NMS Plan implementation dates would similarly not take disciplinary action against their members for failing to commence reporting to the CAT prior to May 20, 2020, unless extended.

    While the SEC and SRO relief currently extends to May 20, 2020, broker-dealers should be mindful that the production readiness testing and certification process for CAT should be conducted 14 days prior to reporting.

    Conclusion

    Due to the impact of COVID-19 on broker-dealers and other market participants, the SEC and relevant SROs have effectively delayed the implementation of the CAT NMS Plan until May 20, 2020, and indicated that the relief may be extended beyond that date. For broker-dealers that have already completed the testing and certification process and want to start reporting to CAT, the CAT production environment will be ready to accept Reportable Event information on April 20, 2020. Broker-dealers wishing to take advantage of the delayed implementation should be prepared to start the production readiness testing and certification process on May 6, 2020 so that they will be ready to report into the CAT production environment on May 20, 2020.

    The SEC, like other federal and state regulators, will continue monitoring the COVID-19 situation and may, if necessary, further extend the time period for any of the CAT no-action relief granted. Schulte Roth & Zabel continues to monitor regulatory developments in connection with COVID-19 and the CAT and will provide further updates as they come in. However, firms should also independently review any regulatory updates to be mindful of their obligations under SEC rules as well as other regulatory regimes.

    Authored by Julian Rainero, Craig S. Warkol, Derek N. Lacarrubba, David S. Sieradzki, William J. Barbera and Akshay Ramanan.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    [1] See SEC no-action letter (March 16, 2020), available here.

    [2] See Letter from the Operating Committee for the CAT NMS Plan (March 16, 2020), available here.

    [3] See SIFMA’s “Firm’s Guide to the Consolidated Audit Trail (CAT),” (Aug. 20, 2019), available here.

    [4] Phases 2a-2e of the Phased Reporting are described in Table 1: Industry Specifications Phased Approach in the CAT Reporting Technical Specifications for Industry Members (version 2.2.1 r3) (Jan. 31, 2020); Table 1: Industry Specifications Phased Approach, CAT Reporting Technical Specifications for Industry Member (version 3.0.0) (Jan. 31, 2020); and Table 1: Industry Customer & Account Specifications Phased Approach, CAT Reporting Customer & Account Technical Specifications for Industry Members (Version 1.0) (Jan. 23, 2020) (collectively with amendments, “Industry Member Technical Specifications”), each of which is available here. The Industry Member Technical Specifications also provide detailed guidance regarding the data required to be reported for each phase.

    [5] The SEC defines a small broker-dealer as a broker or dealer that (a) had total capital (net worth plus subordinated liabilities) of less than $500,000 on the date in the prior fiscal year as of which its audited financial statements were prepared pursuant to Exchange Act rule 17a-5(d) or, if not required to file such statements, a broker or dealer that had total capital (net worth plus subordinated liabilities) of less than $500,000 on the last business day of the preceding fiscal year (or in the time that it has been in business, if shorter); and (b) is not affiliated with any person (other than a natural person) that is not a small business or small organization as defined in Exchange Act rule 0-10.

    [6] Specifically, Large Broker-Dealers and Small Broker-Dealers would be required to submit Phase 2a member data.

    See also fn 7 re: scope of reporting member data in Phase 2a. See also Letter from Michael Simon, Chair, CAT NMS Plan Operating Committee, to Vanessa Countryman, Secretary, Securities and Exchange Commission (Feb. 19, 2020), available here.

    [7] This requirement and deadline would be applicable only to Large Broker-Dealers and Small Broker-Dealers required to record and report information to OATS pursuant to applicable SRO rules.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

     

     

    In depth
    Authors

    William J. Barbera

    Partner

    New York – 919 Third Avenue

    More insights

  • Short-Selling — Update — Belgium, France, Greece and Italy

    Short-Selling — Update — Belgium, France, Greece and Italy

    ARTICLE / CLIENT ALERT

    Short-Selling — Update — Belgium, France, Greece and Italy

    March 18, 2020

    Read time: 3 min

    Key takeaways
    Overview

    Three EU regulators have announced extensions of their short-selling bans with effect from today further to yesterday’s announcement by CNMV in Spain. Greece has also announced a short-selling ban.

    Belgium

    The ban applies until 17 April 2020 and covers companies listed on Euronext Brussels and Euronext Growth. It prohibits short-selling, including through derivatives, depository receipts or any other types of transactions which have the effect of conferring a financial advantage in the event of a decrease in the price of the restricted securities. Short transactions relating to equity indices are covered if the restricted securities represent more than 20% of the index.

    The FSMA notice is available here.

    France

    The ban applies until the close of business on 16 April 2020 and covers all shares admitted to trading on French trading venues. It prohibits creation or increase of net-short positions, meaning that all forms of shorting, including through derivatives and depository receipts, are covered. Shorting through equity indices or baskets is covered by the ban, but only if the restricted stocks represent more than 50% of the index or basket.

    The AMF notice is available here.

    Greece

    The ban applies until 24 April 2020 and covers shares admitted to trading on the Athens Stock Exchange. It prohibits creation or increase of net-short positions (including on an intra-day basis). Short-selling transactions via derivatives, depository receipts and indices are covered by the ban.

    The HCMC notice is available here.

    Italy

    The ban applies until the close of trading on 18 June 2020 and covers a list of shares attached to the notice. The Consob notice is available here.

    It prohibits creation or increase of net-short positions, including through derivatives and depository receipts, except (i) delta-neutral positions used to cover a long position in a convertible bond or (ii) positions used to cover long positions in subscription rights. Net-short positions held through indices are covered if the restricted securities represent more than 20% of the index.

    Authored by Anna Maleva-Otto, Brian T. Daly, Julian Rainero and Craig Stein.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    This communication is issued by Schulte Roth & Zabel LLP and Schulte Roth & Zabel International LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP and Schulte Roth & Zabel International LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Craig Stein

    Partner

    New York – 919 Third Avenue

    More insights

  • Data Security: Update for Private Fund Managers — NY SHIELD Act

    Data Security: Update for Private Fund Managers — NY SHIELD Act

    ARTICLE / CLIENT ALERT

    Data Security: Update for Private Fund Managers — NY SHIELD Act

    March 18, 2020

    Read time: 7 min

    Key takeaways
    Overview

    Numerous data protection laws call for “reasonable” or “adequate” security controls, but are not specific about what those terms mean. New York’s Stop Hacks and Improve Electronic Data Security Act (“SHIELD Act”),[1] the data security requirements of which become effective March 21, 2020, stands out among data protection laws because it provides specific safeguards that should be taken as part of a “reasonable” information security program.[2]

    What Is the SHIELD Act?

    The SHIELD Act is a data security law that takes effect on March 21, 2020, and requires businesses that own or license electronic “private information”[3] of a New York resident, regardless of where that business is located or conducts business, to meet specific data security requirements.[4]

    Most Private Fund Managers Are Not Covered by the SHIELD Act’s Data Security Requirements

    The SHIELD Act’s data security requirements exempt businesses that are subject to, and maintain data security programs that are in compliance with, the Privacy Rule of the Gramm-Leach-Bliley Act (“GLBA”).[5] This means that most private fund managers will not be required to comply with these requirements of the SHIELD Act.[6]

    Fund managers do, however, remain subject to New York’s breach notification requirements, as amended by the SHIELD Act.[7] Managers who experience a cybersecurity incident will want to consult these updated requirements.

    The SHIELD Act Still Provides Useful Guidance for Exempted Fund Managers

    While most private fund managers will be exempted from the data security requirements of the SHIELD Act, it can serve as a helpful point of reference for what a regulator would view as “reasonable” safeguards under federal or other state laws.

    The Elusive “Reasonable” Standard in Data Security

    Several existing data security regulations call on those private fund managers to develop and implement “reasonable” or “appropriate” security procedures and practices, but provide no guidance as to what that means. For example, the California Consumer Privacy Act (“CCPA”) creates a private right of action for consumers whose personal information has been subject to unauthorized access or disclosure as a result of the covered business’ failure to maintain reasonable security procedures. The CCPA, however, does not define “reasonable security procedures.”[8] Similarly, the European Union’s General Data Protection Regulation (“GDPR”) requires a level of security that is “appropriate” to the risks presented by processing, but does not specify the security measures that should be in place.

    The SHIELD Act requires covered businesses to “develop, implement and maintain reasonable safeguards to protect the security, confidentiality and integrity” of private information. A business that implements “reasonable” administrative, technical and physical security measures will be deemed to be in compliance with the statute.[9] Unlike other statutes and regulatory guidance, however, the SHIELD Act goes further to delineate the following 14 specific examples of “reasonable” measures.

    Reasonable Administrative Safeguards:

    • Designate an employee to coordinate the security program;
    • Identify reasonably foreseeable internal and external risks;
    • Assess the sufficiency of safeguards in place to control the identified risk;
    • Train and manage employees in the security program procedures;
    • Select service providers capable of maintaining appropriate safeguards, and require those safeguards by contract; and
    • Adjust the security program in light of the business changes or new circumstances.

    Reasonable Technical Safeguards:

    • Assess risks in network and software design;
    • Assess risks in information processing, transmission, and storage;
    • Detect, prevent, and respond to attacks or system failure; and
    • Regularly test and monitor the effectiveness of key controls and systems and procedures.

    Reasonable Physical Safeguards:

    • Assess risks of information storage and disposal;
    • Detect, prevent, and respond to intrusions;
    • Protect against unauthorized access to or use of private information during or after the collection, transportation, and destruction or disposal of the information; and
    • Dispose of private information within a reasonable amount of time after it is no longer needed for business purposes by erasing electronic media so that the information cannot be read or reconstructed.

    Private fund managers can compare the specific safeguards above to their current information security program and consider what updates would be (or, if they are covered by the SHIELD Act, are) needed to satisfy the SHIELD Act standards.[10]

    Authored by Brian T. Daly, Marc E. Elovitz, Edward H. Sadtler and Kelly Koscuiszka.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    [1] Stop Hacks and Improve Electronic Data Security Act, N.Y. Gen Bus. Law §§ 899-aa & 899-bb.

    [2] The SHIELD Act also amends New York’s breach notification law, effective Oct. 23, 2019, to expand the scope of information and the persons and businesses covered by the existing law. Id. § 899-a

    [3] The definition of “private information” was expanded under the SHIELD Act to mean either (i) any unencrypted (or encrypted with a key that has been accessed) information concerning a natural person which, because of name, number, personal mark, or other identifier, can be used to identify such natural person in combination with any one or more of the following data elements: (1) social security number; (2) driver’s license number or non-driver identification card number; (3) account number, credit or debit card number (in combination with information that would permit access to an individual’s financial account); (4) account number, credit or debit card number (if circumstances exist wherein such number could be used to access an individual’s financial account without additional information); or (5) biometric information; or (ii) a user name or e-mail address in combination with a password or security question and answer that would permit access to an online account.

    [4] The reach of the data security requirements of the SHIELD Act are broader than New York’s prior cybersecurity regulations, the New York Department of Financial Services Cybersecurity Regulations, 23 NYCRR Part 500, both in the expanded definition of what type of information is covered and in reaching companies whose only connection to New York is that they have private information of New York residents.

    [5] Privacy of Consumer Financial Information Rule, 16 C.F.R. Part 313 (“Privacy Rule”).

    [6] Most fund managers are subject to the Privacy Rule, as financial institutions that collect “nonpublic personal information” about natural persons to provide a financial product or service. Fund managers that are not subject to, or are uncertain whether they are subject to the Privacy Rule, will want to consult legal counsel to determine what requirements they may have under the data security requirements of the SHIELD Act.

    [7] N.Y. Gen Bus. Law § 899-aa.

    [8] See our Dec. 6, 2019, Alert for a more general overview of CCPA-related considerations for private fund managers.

    [9] The SHIELD Act does not provide a private right of action. Only the New York Attorney General can bring an action to enjoin violations and to obtain civil penalties (which can be up to $5,000 per violation).

    [10] The NIST cybersecurity framework, a voluntary framework developed through collaboration between the government and private sector, is another helpful resource for fund managers seeking more detailed operational guidance.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Marc E. Elovitz

    Partner

    New York – 919 Third Avenue

    Kelly Koscuiszka

    Partner

    New York – 919 Third Avenue

    More insights

  • UK Update: Guidance for FCA-Regulated Managers (COVID-19)

    UK Update: Guidance for FCA-Regulated Managers (COVID-19)

    ARTICLE / CLIENT ALERT

    UK Update: Guidance for FCA-Regulated Managers (COVID-19)

    18 March 2020

    Read time: 6 min

    Key takeaways
    Overview

    Our previous publications and Alerts discussed various considerations that hedge fund managers and private equity sponsors generally should take into account when preparing for business interruptions that may be associated with the coronavirus outbreak. The following additional considerations will apply to managers that are headquartered in the United Kingdom or have group affiliates regulated by the UK Financial Conduct Authority (“FCA”). These considerations apply to all FCA-authorised firms to which they are relevant, irrespective of their regulatory permissions.

    Operational Resilience

    The FCA, Bank of England and HM Treasury recently published a supervisory statement addressing the developments relating to the spread of COVID-19. This statement made it clear that firms were expected to continue to comply with their ongoing regulatory requirements despite market volatility and irrespective of the business disruption meaning that many managers have implemented certain aspects of their business continuity plans (“BCPs”).

    In another statement published on 17 March 2020, the FCA again highlighted the importance of operational resilience. Firms must have contingency plans to deal with major events and the regulator expects these plans to have been tested. The FCA and PRA continue their work on the rules aimed at strengthening operational resilience of UK firms proposed in CP19/32.

    Given the recent market volatility, managers should be vigilant in challenging the assumptions that underpin their BCPs, as certain contingencies may need to be adapted as the spread of COVID-19 continues. The FCA has indicated that they intend to engage with a wide range of firms to review their BCPs in the near term. Managers should use this warning as an impetus to document their review and stress-test their BCPs.

    Compliance with Telephone-Recording Obligations

    Managers should ensure they can continue to record and monitor relevant communications if staff works from home or at alternative sites. Managers that currently do not record mobile communications should consider providing key employees with recording software or equipment as part of their BCPs. Managers who are unable to comply with the telephone recording requirements need to notify the FCA.

    Transactions and Orders

    The FCA has not so far offered any relief or forbearance with regards to compliance with record-keeping or transaction reporting obligations, although it has promised to work with trade associations, industry bodies and firms to resolve any issues as they come up. In the meanwhile, managers are expected to continue entering orders and transactions promptly into the relevant trading systems, and maintain full records of orders and transactions. As managers are moving to alternative sites and work from home arrangements, they must not lose sight of the broader control environment for trading and operations. For example, when reviewing their BCP arrangements, firms should separately consider the increased risk of trade errors where a remote working policy has been implemented.

    Trading Surveillance

    Managers must still take all steps to prevent market abuse. This could include enhanced monitoring or retrospective reviews. The market surveillance teams at the FCA continue to monitor for market abuse and other misconduct and firms are still receiving information requests relating to their trading activities. These must be responded to on a timely basis.

    Regulatory Reporting

    Firms should assume that the usual reporting deadlines will apply. If a firm is experiencing difficulties in submitting their regulatory data, the FCA expects the firm to maintain appropriate records during the relevant period and submit the data as soon as possible. Firms are advised against delaying their filings unnecessarily, and should contact the FCA if they are not able to comply.

    Outsourcing

    Managers that rely on third-party service providers for performance of material functions will need to engage with them to ensure these business services will not suffer interruptions. Managers should review service provider contracts for any “material adverse change” or “force majeure” clauses, obtain the necessary service continuity assurances from service providers, and take these matters into account when stress-testing their business continuity and disaster recovery scenarios. Irrespective of any outsourcing, responsibility remains with the regulated manager.

    Access to Compliance Support

    Managers must ensure that trading and other personnel are able to access the compliance function (and vice versa) even where they have implemented a remote working policy. Personnel should be briefed on all arrangements and systems for communications with others within the firm and provided with emergency contact details for key persons within the firm. Managers will need to review the legal basis on which personal data is being shared and should look to update internal data protection policies (e.g., employee privacy notices) where necessary.

    Temporary Trading Restrictions

    Firms should keep regulatory announcements relating to emergency measures, such as short-selling bans, position limits, market suspensions and position disclosure obligations, under constant review. In particular, firms are advised to monitor the FCA’s news page and ESMA’s press-release page, as well as the websites of other regulators, and any updates circulated by their brokers and counterparties in the relevant markets. Managers should ensure that staff or external service providers are on standby to make modifications to their portfolio/execution management systems (e.g., automated tracking of positions) to ensure compliance with such emergency measures.

    Managers should also review their trading documentation and exchange rules, and stress-test the impact of scenarios involving market interruptions on their portfolios.

    Authored by Josh Dambacher, Christopher Hilditch and Anna Maleva-Otto.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    This communication is issued by Schulte Roth & Zabel LLP and Schulte Roth & Zabel International LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP and Schulte Roth & Zabel International LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Josh Dambacher

    Partner

    London – One Eagle Place

    Christopher Hilditch

    Partner

    London – One Eagle Place

    More insights

  • Regulated Funds: SEC Provides Conditional Relief in Response to COVID-19

    Regulated Funds: SEC Provides Conditional Relief in Response to COVID-19

    ARTICLE / CLIENT ALERT

    Regulated Funds: SEC Provides Conditional Relief in Response to COVID-19

    March 18, 2020

    Read time: 8 min

    Key takeaways
    Overview

    On March 13, 2020, the U.S. Securities and Exchange Commission issued an order providing an exemption for registered investment companies and business development companies (“Regulated Funds”) from certain requirements under the Investment Company Act of 1940, as amended (“1940 Act”), in light of operational challenges arising in connection with the current coronavirus outbreak (“Order”).[1] Among other things, the Order provides relief from the requirement to hold in-person meetings of Regulated Fund boards of directors for certain 1940 Act approvals, as well as extends the transmittal and filing deadlines for certain registered fund reports.

    In-Person Voting Requirements

    Pursuant to the Order, for the period from the date of the Order through June 15, 2020 (subject to extension by the SEC), Regulated Funds are exempted from the in-person voting requirements of the 1940 Act with respect to the approval of a fund’s advisory agreement, interim advisory agreement and 12b-1 distribution plan and the selection of a fund’s independent public accountant. In lieu of voting at an in-person meeting, the votes to approve these matters must instead be cast at a meeting utilizing any means of communication that allows the participating directors to hear each other simultaneously during the meeting. This exemptive relief is conditioned on being “necessary or appropriate due to circumstances related to current or potential effects of COVID-19.” In addition, if a Regulated Fund relies on this relief, the fund’s board, including a majority of the independent directors, must ratify the action taken pursuant to this exemption at the board’s next in-person meeting. The Order formalizes guidance on this matter that was recently issued by the Staff of the Division of Investment Management of the SEC (“Staff Statement”).[2] Because the Order provides exemptive relief (in contrast with the prior Staff Statement), it obviates possible concerns relating to the validity of approvals made during the COVID-19 situation other than at in-person meetings. For more information about the Staff Statement, please refer to the SRZ Alert available here.

    Forms N-CEN and N-PORT Filing Requirements

    The Order states that “disruptions to transportation, and limited access to facilities, personnel, and third party service providers as a result of COVID-19 could hamper the efforts of registered funds with filing obligations to meet their filing deadlines,” while also noting the importance of providing timely investment information to investors. For funds that are “unable to meet a filing deadline due to circumstances related to current or potential effects of COVID-19” with respect to filings with a due date on or after the date of the Order but on or prior to April 30, 2020, the Order provides a temporary exemption from the Form N-CEN and Form N-PORT filing requirements, subject to the following conditions.

    • The fund must promptly notify the SEC staff by email as described further below;
    • Disclosure must be included on the fund’s public website, briefly stating that the fund is relying on the Order and describing the reasons it could not file its reports on a timely basis;
    • The delayed Form N-CEN or Form N-PORT must be filed as soon as practicable, but not later than 45 days after the original due date; and
    • The delayed Form N-CEN or Form N-PORT must include a statement that the fund relied on the Order and provide the reasons why it was unable to file the report on a timely basis.

    Transmission of Annual and Semi-Annual Reports

    Citing the same concerns relating to the filing of Forms N-CEN and N-PORT, the Order also provides temporary relief from the requirement to transmit annual and semi-annual reports to investors with respect to reports with a due date on or after the date of the Order but on or prior to April 30, 2020, for funds unable to prepare or transmit the report because of COVID-19 issues. Funds delaying the transmission of investor reports in reliance on the Order must meet the following conditions.

    • The fund must promptly notify the SEC staff by email as described further below;
    • The fund must include a statement on the fund’s public website briefly stating that it is relying on the Order and the reasons why it could not prepare and transmit the report on a timely basis; and
    • The fund must transmit the delayed report to investors as soon as practicable, but no later than 45 days after the original due date, and file the report with the SEC within 10 days of its transmission to investors.

    Timing of Filing Form N-23C-2

    From the date of the Order through June 15, 2020, Regulated Funds are exempted from the requirement to file with the SEC notices of their intention to call or redeem securities at least 30 days in advance if such company files a Form N-23C-2 with the SEC fewer than 30 days prior to, including the same business day as, the fund’s call or redemption of securities, subject to meeting the following conditions.

    • The Regulated Fund must promptly notify the SEC staff via email at IM-EmergencyRelief@sec.gov stating that the fund is relying on the Order and including a brief description of the reasons why it needs to file a Form N-23C-2 fewer than 30 days in advance of the date set by the Regulated Fund for calling or redeeming the securities of which it is the issuer;
    • The Regulated Fund ensures that the filing of the Form N-23C-2 on an abbreviated time frame is permitted under relevant state law and the Regulated Fund’s governing documents; and
    • The Regulated Fund files a Form N-23C-2 that contains all the information required by Rule 23c-2 prior to: any call or redemption of existing securities; the commencement of any offering of replacement securities; and providing notification to the existing shareholders whose securities are being called or redeemed.

    Delivery of Fund Prospectuses

    The Order states that a delay in the delivery of the current prospectus of a fund to an existing shareholder of the fund, where the prospectus cannot be timely delivered because of circumstances relating to COVID-19, would not be a basis for an enforcement action by the SEC, if the following conditions are met.

    • The fund notifies the SEC staff by email as described further below;
    • The fund publishes on its public website that it intends to rely on the SEC position contained in the Order and briefly states the reasons why it could not deliver the prospectus on a timely basis;
    • The fund publishes on its public website its current prospectus; and
    • Delivery of the prospectus was originally required to be made on or after the date of the Order but on or prior to April 30, 2020, and the prospectus is delivered to investors as soon as practicable, but not later than 45 days after the date originally required.

    Notification to SEC Staff Regarding Reliance on Order

    A fund relying on the Order with respect to the delayed filing or transmission of its reports or relying on the SEC position contained in the Order with respect to delayed prospectus delivery must promptly notify the SEC staff via email at IM-EmergencyRelief@sec.gov stating:

    • That it is relying on the Order or SEC position, as applicable;
    • A brief description of the reasons why it could not file or transmit its report on a timely basis, or why it or any other person required could not deliver the prospectus on a timely basis, as applicable; and
    • The estimated date by which it expects to file or transmit the report, or expects the prospectus to be delivered, as applicable.

    Issues to Consider in Relying on the Order

    Funds should consider the potential benefits and drawbacks of relying on the Order with respect to delayed filings of a fund’s Forms N-CEN and N-PORT or its shareholder reports, or delayed prospectus delivery, given the requirements to publicly disclose the reasons for the need to rely on the relief. Funds should consider whether a filing or transmission delay could reflect negatively on the perceived effectiveness of the fund’s business continuity procedures and planning. In addition, as noted in the Order, funds must continue to evaluate their obligations to make materially accurate and complete disclosures in their filings, in accordance with the federal securities laws. 

    Authored by Karen Spiegel.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    [1] 1940 Act Release No. 33817 (Mar. 13, 2020), available here.

    [2] Division of Investment Management Staff Statement on Fund Board Meetings and Unforeseen or Emergency Circumstances Related to Coronavirus Disease 2019 (COVID-19) (Mar. 4, 2020), available at here.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors
    More insights

  • Financial and Commercial Considerations for Successfully Navigating COVID-19

    Financial and Commercial Considerations for Successfully Navigating COVID-19

    ARTICLE / CLIENT ALERT

    Financial and Commercial Considerations for Successfully Navigating COVID-19

    March 18, 2020

    Read time: 5 min

    Key takeaways
    Overview

    Because the lasting impact and full scope of COVID-19 remains largely unknown, companies must be prepared to deal with any challenges that may arise, particularly those that could result in unforeseen financial distress. We offer a chart that outlines considerations that will help companies proactively and successfully navigate the potential impacts of the spread of COVID-19.

    In depth

    Following the recent outbreak of the Coronavirus (COVID-19), companies are focused on the financial and commercial implications, including problematic supply chain disruption, workforce disruption and sweeping travel restrictions on both goods and people.

    Because the lasting impact and full scope of COVID-19 remains largely unknown, companies must be aptly equipped to deal with these and any other challenges that may arise, particularly those that could result in unforeseen financial distress. Being proactive in the coming months can help companies preserve value and prevent additional harm. Impacted industries include:

    • Travel (airlines, hotel, cruise lines, tour operators)
    • Food and Beverage/Restaurants
    • Entertainment (movie theatres, live sport venues and teams)
    • Real Estate
    • Transportation/Shipment
    • E-Commerce (supply and delivery disruption)
    • Oil and Gas/Power
    • Retail (especially luxury sector)
    • Pharma/Life Sciences/Healthcare
    • Manufacturing (supply chain disruption and a drop in demand)
    • Healthcare (demand/supply and capitation related issues)

    To successfully navigate this uncertainty, management should be prepared to evaluate modifications to current business plans to address changes in operations, potential financial covenant defaults and other possible contract breaches or defaults; regularly update their requisite cash flow forecasts; and monitor their ability to pay upcoming debt maturities or obtain additional financing, as needed.

    The subsequent chart outlines considerations that will help companies proactively and successfully navigate the potential impacts of the spread of COVID-19:

     

    Considerations for Successfully Navigating COVID-19
    Mitigate Supply Chain Disruptions
    • Identify and mitigate any potential supply chain disruption caused by factory closures, travel restrictions or employee shortages due to illness or quarantine.
    • Consider short-term changes to supply chain model to avoid disruption (e.g., replacement suppliers or vendors, other production alternatives).
    • Evaluate and consider impact on vendors’ ability to deliver and customers’ ability to pay on time.
    • Identify and mitigate potential contractual issues arising from delays in production or failure to fulfill outstanding orders (e.g., events of default, notice requirements, applicability of force majeure provisions) and any related consequences of a breach.
    • Review material contracts for any cross-default issues.
    • Implement alternative communication procedures with buyers and suppliers while any travel restrictions remain in effect.
    Consider Potential Financial Obstacles
    • Regularly review actual cash flow status and accurately forecast cash on a regular and rolling basis (e.g., daily) to mitigate potential deficiencies due to supply chain disruption, decreased sales, and extended travel restrictions. For companies with credit facilities, they should assume that their lenders will be requesting 13-week cash flow forecasts and begin prepare these preliminary draft forecasts.
    • Consider implications of missed targets on ability to achieve overall projections outlined in current business plan and update business plan accordingly.
    • Assess implications for the potential delay of business expansion or consolidation and ability to obtain subsequent rounds of financing.
    • Consider impact on working capital of disruption to supply chain and replacement of existing company vendors.
    • Consider cost of significant workforce disruption and its impact on continued operation of business.
    • Consider cost of implementing programs to protect employee health.
    • Carefully review insurance policies to assess potential recoveries for any business disruption and clarify need for additional coverage as situation develops.
    Near-Term Debt Financing Issues to Address
    • Critically review existing debt service obligations to identify ability to make principal and interest payments likely due at the end of March and assess probable consequences of seeking deferrals.
    • Critically review potential covenant defaults resulting from operational disruption. Review potential options for increasing EBITDA for losses and expenses in connection with COVID-19.
    • Review current access to revolving lines of credit and delayed-draw term loans and consider drawing down prior to next reporting period (while being mindful of impact on any applicable financial covenants). Review cash management structure to determine ability to keep cash in deposit accounts that are not part of a lender’s security package.
    • Consider whether COVID-19 will impact ability to bring down representations and warranties (including those related to solvency and no material adverse effect).
    • For asset-based loans (ABLs), carefully review excess availability or liquidity triggers for avoiding springing financial covenants, cash dominion, increased reporting and inspection rights caused by increased draws.
    Long-Term Debt Financing Issues to Address
    • Consider whether there are any upcoming debt maturities in the near future (e.g., next nine to 12 months) and assess ability to address them.
    • Consider impact of decreasing loan bids and falling bond prices in the secondary loan market on traded debt and ability to retire debt under par.
    • Engage with lenders and other company stakeholders to encourage proactive discussions regarding potential rescheduling of debt or obtaining alternative financing sources.
    Authors

    Michael L. Boykins

    Partner

    Chicago

    Stephanie S. McCann

    Partner

    Chicago

    Gary B. Rosenbaum

    Partner

    Los Angeles

    Joshua Samis

    Partner

    Chicago

    More insights

  • FDA Offers Laboratories, Manufacturers New Flexibility to Expedite COVID-19 Testing

    ARTICLE / CLIENT ALERT

    FDA Offers Laboratories, Manufacturers New Flexibility to Expedite COVID-19 Testing

    March 17, 2020

    Read time: 4 min

    Key takeaways
    Overview

    On March 16, 2020, the US Food and Drug Administration (FDA) announced several initiatives intended to further increase access to validated COVID-19 testing. This alert addresses key components of the announcement, which included announcements intended to help clinical laboratories and test kit manufacturers get tests to patients more quickly.

    In depth

    On March 16, 2020, the US Food and Drug Administration (FDA) announced several initiatives intended to further increase access to validated COVID-19 testing. Key components of the announcement, which follows on the heels of recent FDA announcements intended to increase patient access to testing, include the following:

    • Authorizing states to allow high-complexity clinical laboratories to offer COVID-19 tests without first obtaining an Emergency Use Authorization (EUA). On March 12, 2020, FDA announced that it would allow New York State to authorize certain laboratories in that state to offer validated COVID-19 testing without obtaining an EUA from FDA, provided such laboratories met certain requirements established by the state. The FDA’s March 16, 2020 announcement extends similar authority to the remaining 49 states, provided such states affirmatively choose to take responsibility for tests developed and used by laboratories in their states. The process will be established individually by each state and will not necessarily need to mirror New York State’s process. States may allow clinical laboratories that meet Clinical Laboratory Improvement Amendments of 1988 (CLIA) requirements to perform high-complexity testing in those states (1) to engage directly with appropriate state authorities instead of with the FDA, and (2) to offer their tests without first obtaining an EUA.FDA requests that states notify the agency if they intend to use this flexibility to expedite COVID-19 testing. While FDA will not review the process adopted by any individual state to review laboratory requests to begin testing, the agency expects states to require laboratories to validate their tests prior to clinical use.
    • Authorizing manufacturers to distribute validated COVID-19 test kits prior to submission of an EUA. Expanding the policy FDA previously announced for CLIA-certified clinical laboratories that perform high complexity testing, FDA will now allow commercial test kit manufacturers to distribute COVID-19 test kits for a reasonable period of time after the manufacturer’s validation of the test, provided that the manufacturer (1) is preparing an EUA request and (2) provides instructions for use of the test and data about the test’s performance characteristics on the manufacturer’s website. Following completion of assay validation, manufacturers should notify FDA (e.g., via email to CDRH-EUA-Templates@FDA.HHS.GOV) that their assay has been validated and that they intend to begin distribution. FDA requests that manufacturers submit a completed EUA request within 15 business days of notifying FDA that the assay has been successfully validated. To facilitate manufacturer preparation of the EUA, FDA has posted a template submission on its website. If FDA is not able to authorize an EUA, FDA would expect the manufacturer to suspend distribution and conduct a recall of the test.
    • Providing recommendations for development of serology tests. Prior to March 16, 2020, FDA guidance primarily focused on nucleic acid-based tests for the detection of COVID-19. However, the agency also acknowledged that some commercial manufacturers and laboratories are seeking to develop antibody tests for COVID-19. FDA notes that it does not intend to object to the development and use of COVID-19 antibody tests, provided the test has been validated, the test developer provides notice to the FDA, and warning statements are included with the tests. Such warnings may include statements that the test has not been reviewed by FDA, that negative results do not rule out COVID-19 infection, that results from antibody testing should not be used as the sole basis to diagnose or exclude COVID-19 infection or to inform infection status, and that positive results may be due to past or present infection with non-COVID-19 coronavirus strains. FDA also provides specific recommendations for antigen detection and serology validation studies, including limit of detection/analytical sensitivity, cross-reactivity/analytical specificity, microbial interference or clinical agreement studies, as may be applicable.
    Authors

    Michael W. Ryan

    Partner

    Washington, DC

    More insights

  • Three Evolving Concepts in Intercreditor Agreements

    Three Evolving Concepts in Intercreditor Agreements

    ARTICLE

    Three Evolving Concepts in Intercreditor Agreements

    March 17, 2020

    Read time: 1 min

    Key takeaways
    Overview
    In depth
    Authors
    More insights

  • Section 1135 Waivers Now Available, but Some Waivers May Require Approval

    Section 1135 Waivers Now Available, but Some Waivers May Require Approval

    ARTICLE / CLIENT ALERT

    Section 1135 Waivers Now Available, but Some Waivers May Require Approval

    March 17, 2020

    Read time: 12 min

    Key takeaways
    Overview

    On March 13, 2020, President Donald Trump declared a national emergency under the National Emergencies Act and made an emergency determination under the Stafford Act. This announcement follows the January 31, 2020, declaration of a public health emergency under the Public Health Service Act by the Secretary of the US Department of Health and Human Services (HHS). These actions opened the door for the authorization of waivers of certain Medicare, Medicaid and Children’s Health Insurance Program (CHIP) requirements as provided by Section 1135 of the Social Security Act (collectively, Section 1135 waivers). Shortly after the presidential declaration on March 13, the Centers for Medicare and Medicaid Services (CMS) announced a set of waivers specific to the COVID-19 pandemic (COVID-19 waivers).

    As of March 16, 2020, HHS and the Centers for Medicare and Medicaid Services (CMS) have released the full text of the Section 1135 waivers, as well as guidance documents addressing implementation of some, but not all, of the Section 1135 waiver provisions. [Review the following waivers released to date: “COVID-19 emergency declaration blanket waivers for health care providers” and “Medicare fee-for-service response to the public health emergency on COVID-19“]. HHS will implement the Section 1135 waivers through a series of releases from different divisions within the agency, creating an ongoing need for providers to monitor the process for requesting or operating under the available Section 1135 waivers. Although the process for using the Section 1135 waivers is evolving, CMS has made clear that for all services being provided under the Section 1135 waiver authority, providers must include claim-level identifiers on claims to Medicare for payment of the services.

    In depth

    Background

    Section 1135 waivers provide a temporary relaxation of certain—but not all—healthcare regulatory requirements in the event of a declared disaster or emergency. In the past, the waivers have been issued for natural disasters and pandemics, such as Hurricane Katrina and H1N1 influenza, and focused on specific concerns related to those events and their impact on the healthcare system and provision of care. Certain of the COVID-19 waivers applicable to providers and services governed by Medicare payment laws are styled as “blanket” waivers, applicable nationally to a broad group of providers, reflecting the nationwide effects of the COVID-19 crisis. The process for using or requesting other COVID-19 waivers, such as those related to the Emergency Treatment and Labor Act (EMTALA), HIPAA and the Stark Law, remain less clear and will likely be subject to future HHS guidance. In addition, the COVID-19 waivers applicable to providers and services governed by Medicaid laws require states to individually apply for relief.

    Case-by-Case Versus Blanket Waiver or Modification

    CMS may implement Section 1135 waivers in several ways, although all require that CMS determine that a provider has been affected by the disaster or emergency that prompted the issuance of the waivers. CMS has the option to issue Section 1135 waivers that require providers to request and receive approval for relief on a case-by-case basis, or CMS can implement “blanket” waivers. Blanket waivers may be issued when CMS has determined that all similarly situated providers in an identified emergency area need such a waiver or modification. Often, as with natural disasters, the “emergency area” is limited. In other cases, such as pandemics, the emergency area may be much more expansive.

    CMS considers several factors when determining whether to provide a specific or blanket waiver or modification, including the scope and severity of the emergency, the expected duration, feedback from the state survey agency and state and federal emergency response officials, and supporting data gathered by state provider associations.

    Any waivers or modifications issued by CMS pertain only to federal requirements, and providers must ensure that any steps they take in accordance with the waivers also comport with state law.

    “Blanket” COVID-19 Waivers

    On March 13, 2020, subsequent to the president’s declaration of a national emergency, CMS released information on the “blanket” Section 1135 waivers that would be made available to providers in relation to the COVID-19 pandemic. The COVID-19 blanket waivers cover the following provisions of Medicare law and regulation:

    • Skilled Nursing Facilities (SNFs): Waiver of the three-day prior hospitalization requirement for coverage of an SNF stay. Beneficiaries may be transferred because of the emergency without a prior qualifying hospital stay, and certain beneficiaries’ SNF coverage, once benefits are exhausted, may be renewed. CMS also waived the timeframe requirements for Minimum Data Set assessments and transmission.
    • Critical Access Hospitals (CAHs): Waiver of the 25-bed limit requirement for CAHs and waiver of 96-hour limit on length of stays.
    • Housing Acute Care Patients in Excluded Distinct Part Units: Waiver to allow acute care hospitals to house acute care inpatients in excluded distinct part units. The Inpatient Prospective Payment System hospital is instructed to annotate in the medical record that the patient is an acute care inpatient being housed in the excluded unit because of capacity issues related to the emergency.
    • Durable Medical Equipment (DMEPOS): Authorization for contractors to waive the face-to-face visit, new physician’s order or medical necessity requirements for replacement of DMEPOS when the DMEPOS is lost, destroyed, irreparably damaged, or otherwise rendered unusable or unavailable as a result of the emergency.
    • Care for Excluded Inpatient Psychiatric Unit Patients in the Acute Care Unit of a Hospital: Ability for acute care hospitals to relocate inpatients from excluded distinct part psychiatric units to acute care beds and units if necessary. The affected hospital is instructed to annotate the medical record to indicate the patient is a psychiatric inpatient being cared for in an acute care bed because of capacity or exigent circumstances related to the emergency.
    • Care for Excluded Inpatient Rehabilitation Unit Patients in the Acute Care Unit of a Hospital: Ability for acute care hospitals to relocate inpatients from excluded distinct part rehabilitation units to acute care beds and units if necessary. The affected hospital is instructed annotate the medical record to indicate the patient is a rehabilitation inpatient being cared for in an acute care bed because of capacity or exigent circumstances related to the emergency.
    • Supporting Care for Patients in Long-Term Care Acute Hospitals (LTCHs): Ability for LTCHs to exclude patient stays where an LTCH admits or discharges patients in order to meet the demands of the emergency from the 25-day average length of stay requirement otherwise applicable to LTCHs.
    • Home Health Agencies (HHAs): Relief to HHAs regarding the timeframes related to OASIS Transmission and allowing Medicare Administrative Contractors to extend the auto-cancellation date of Requests for Anticipated Payment during emergencies (note that this is an extension of time and not a waiver of completion).
    • Provider Locations: Temporary waiver of the requirement that out-of-state providers be licensed in the state where they provide services when they are licensed in another state. This temporary waiver applies to Medicare and Medicaid reimbursement requirements but not to CHIP or state licensing requirements.
    • Provider Enrollment: Establishment of a toll-free hotline for non-certified Part B suppliers, physicians and non-physician practitioners to enroll and receive temporary Medicare billing privileges. Waiver of the application fee, finger-based criminal background checks and site visit typically part of the screening requirements. Postponement of all revalidation actions. Ability for licensed providers to render services outside of their state of enrollment, and expedited handling of any pending or new applications from providers.
    • Medicare Appeals in Fee-for-Service, Medicare Advantage and Part D: Extension of time to file an appeal and waiver of timeliness for requests for additional information to adjudicate the appeal. Appeals will be processed even with incomplete Appointment of Representation forms, but communicating only to the beneficiary. Requests for appeal that do not meet the required elements will be processed using information that is available. All flexibilities available will be used in the appeal process as if good cause requirements are satisfied.
    • Part B Prescription Refills: Medicare payment may be permitted for replacement prescription fills (for a quantity up to the amount originally dispensed) of covered Part B drugs in circumstances where dispensed medication has been lost or otherwise rendered unusable or unavailable due to the emergency.

    “Case-by-Case” COVID-19 Waivers

    Unlike the blanket waivers issued for Medicare laws described above, the COVID-19 waivers for EMTALA, HIPAA, Stark Law, Medicaid laws or other Medicare requirements subject to waiver under Section 1135, but not expressly designated as part of the blanket waivers, may require “case-by-case” requests and approvals. Providers interested in obtaining waivers of any of the following provisions should consider requesting a waiver, unless HHS opts to release future guidance providing for blanket waivers:

    • EMTALA requirements related to direction or relocation of an individual to another location to receive medical screening pursuant to a state emergency preparedness plan, or for transfer of an individual who has not been stabilized, if the transfer is necessitated by the circumstances of the declared public health emergency
    • Stark Law provisions related to limitations on physician referrals, as determined by CMS to be appropriate
    • Penalties and sanctions related to the provisions of the HIPAA privacy regulations that pertain to (1) the requirements to obtain a patient’s agreement to speak with family members or friends, or to honor a patient’s request to opt out of the facility directory; (2) the requirement to distribute a notice of privacy practices; and (3) the patient’s right to request privacy restrictions or confidential communications
      • Note that the HIPAA waivers are limited to hospitals in designated geographic areas that have hospital disaster protocols in operation and extend only for 72 hours from implementation of the hospital disaster protocol.
    • Conditions of participation, certification requirements, program participation, pre-approval or similar requirements
    • Payment for items and services furnished by out-of-network providers to individuals enrolled in Medicare Advantage plans.

    As to Medicaid program requirements, CMS did not identify limitations on provisions that it will consider waiving within the scope of the provisions set forth in the Section 1135 waiver document itself, but did provide examples of provisions that may be requested for waiver:

    • Waiving prior authorization requirements in fee-for-service programs
    • Permitting providers located out-of-state or -territory to provide care to another state’s Medicaid enrollees affected by the emergency (referring to ability to receive payment)
    • Temporarily suspending certain provider enrollment and revalidation requirements to increase access to care
    • Temporarily waiving requirements that physicians and other healthcare professionals be licensed in the state in which they are providing services, as long as they have an equivalent licensure in another state
    • Temporarily suspending requirements for certain pre-admission and annual screenings for nursing home residents.

    Notice or Request for a Waiver to Apply

    Although not explicitly required by the CMS materials released to date, providers who desire to operate under the blanket COVID-19 waivers for Medicare laws should notify the CMS Regional Office, their Medicare Administrative Contractor (MAC) and, if applicable, their state survey agency of their intent to do so. A list of CMS Regional Office contacts for the waiver process is provided at the end of this article. Notice may be sent via email or letter, and should include the following information:

    • Provider name/type
    • Full address and CCN
    • Contact person
    • Identification of the blanket COVID-19 waivers under which the provider will operate.

    In addition to the above elements of notice, if applicable, providers should simultaneously request “case-by-case” waiver accommodations under EMTALA or relief from other waivable laws, if the relief could be granted under Section 1135 and is not presently included as part of the blanket COVID-19 waivers.

    While notice is sufficient to take advantage of the blanket waivers, providers requesting case-by-case waivers must submit a request to the CMS Regional Office or, if applicable, the state survey agency. It is also advisable to send a copy of the request to the MAC. There is no required format for the request, but it should include the information listed above for the blanket waivers, as well as the justification for the waiver(s) being requested. States that wish to take advantage of the Section 1135 waivers for Medicaid and State CHIP laws must submit requests directly to Jackie Glaze, CMS Acting Director, Medicaid & CHIP Operations Group Center for Medicaid & CHIP Services, by email (Jackie.Glaze@cms.hhs.gov) or mail.

    Should CMS issue specific waivers related to COVID-19 in the future, providers will need to specifically request their application. This article will be updated to reflect those requirements in the event this occurs.

    Regardless of waiver type, providers should keep careful records of beneficiaries who receive services in order to ensure that proper payment is made.

    Claim-Level Identifiers

    In connection with the Section 1135 waivers, CMS requires that providers apply one or both of the following claim-level identifiers to services furnished under the Section 1135 waivers:

    • Condition Code “DR” (disaster related) for institutional billing, i.e., claims submitted using the ASC X12 837 institutional claims format or paper Form CMS-1450
    • Modifier “CR” (catastrophe/disaster related) for Part B billing, both institutional and non-institutional, i.e., claims submitted using the ASC X12 837 professional claim format or paper Form CMS-1500 or, for pharmacies, in the NCPDP format.

    Duration of Waivers

    Waivers typically terminate at the earlier of either the termination of the emergency period or 60 days from the date the waiver or modification is first published. The Secretary of HHS may extend the waiver by notice for additional periods of up to 60 days, up to the end of the emergency period. CMS has not yet provided guidance on how long it may extend COVID-19 waiver authority.

    Key Takeaways

    Section 1135 waivers provide a mechanism for HHS and CMS to accommodate the exigencies experienced by healthcare providers in the event of a disaster or other significant emergency. While other accommodations and flexibility may be exercised by CMS and state survey agencies around these events, Section 1135 permits granting a broad spectrum of potential relief.
    In the case of the COVID-19 waivers, providers that want to take advantage of the opportunities for relief under the Medicare laws should send a notice or request, depending on the waiver required, to CMS (see email addresses below), their MAC and, if applicable, the state survey agency. States interested in seeking waivers under the Medicaid laws may do so through an email request to the Medicaid and CHIP Operations Group.
    _________________________________________________

    ROATLHSQ@cms.hhs.gov (Atlanta RO): Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee

    RODALDSC@cms.hhs.gov (Dallas RO): Arkansas, Louisiana, New Mexico, Oklahoma, Texas

    ROPHIDSC@cms.hhs.gov (Northeast Consortium): Delaware, District of Columbia, Maryland, Pennsylvania, Virginia, West Virginia, New York, New Jersey, Puerto Rico, Virgin Islands, Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont

    ROCHISC@cms.hhs.gov (Midwest Consortium): Illinois, Indiana, Michigan, Minnesota, Ohio, Wisconsin, Iowa, Kansas, Missouri, Nebraska

    ROSFOSO@cms.hhs.gov (Western Consortium): Colorado, Montana, North Dakota, South Dakota, Utah, Wyoming, Alaska, Idaho, Oregon, Washington, Arizona, California, Hawaii, Nevada, Pacific Territories

    Authors

    Sandra M. DiVarco

    Partner

    Chicago

    Emily Jane Cook

    Partner

    Los Angeles, Washington, DC

    More insights

  • CLO Guidance — The Impact of COVID-19 — Considerations for Managers of Collateralized Loan Obligations

    CLO Guidance — The Impact of COVID-19 — Considerations for Managers of Collateralized Loan Obligations

    ARTICLE / CLIENT ALERT

    CLO Guidance — The Impact of COVID-19 — Considerations for Managers of Collateralized Loan Obligations

    March 17, 2020

    Read time: 4 min

    Key takeaways
    Overview

    The recent worldwide outbreak of coronavirus disease 2019 (“COVID-19”) has resulted in extraordinary actions, including quarantines and “social distancing,” which is currently disrupting economic activity in the United States and globally.

    This, coupled with a disruption in the energy industry due to a severe drop in oil prices resulting from a lack of agreement on drilling output limits by certain OPEC nations, is having a negative effect on certain industries.

    On Sunday, March 15, 2020, the Open Market Committee of the Federal Reserve Bank reduced the target range for the federal funds rate to 0.00% — 0.25%, and the U.S. Congress is currently considering emergency legislation to support the economy throughout the crisis. Actions by federal, state and local governments to mitigate the impact of the coronavirus, as well as continued market volatility arising from the spread of coronavirus, are likely to affect collateralized loan obligations (“CLOs”) and their underlying assets. CLO managers should consider the effects this will have on their CLO transactions and should note the following:

    1. CLOs usually carry their collateral obligations (other than collateral obligations purchased at a discount) at par value for purposes of overcollateralization tests; however defaulted collateral obligations are typically counted at market value for overcollateralization tests, and collateral obligations whose ratings are “CCC+” or below (to the extent not treated as defaulted obligations) are also typically adjusted for purposes of the overcollateralization tests.
    2. For CLOs purchasing collateral obligations at deeply discounted prices (below certain threshold prices, depending on the ratings of the obligations) at this time, it is important to recall that these collateral obligations typically will be carried at their purchase price for purposes of the overcollateralization tests.
    3. Should loan prices continue to decline, CLO managers should review their ability to swap discounted collateral obligations with the sale proceeds of a collateral obligation without having to treat the new loan as a discount collateral obligation. In addition, CLO managers should take note of their minimum purchase price criteria.
    4. If CLO loan portfolios deteriorate (whether as a result of price declines, ratings downgrades on individual loans, or a general weakening of obligors’ financial strength) and rating agencies begin to downgrade CLO notes, the ability to trade loans may be suspended if a “restricted trading period” goes into effect under a CLO’s indenture.
    5. CLO managers should review their CLO indentures to determine their ability to agree to amendments, restructurings and workouts in anticipation of loan obligors looking to take certain actions.
    6. Engagement letters for CLOs usually have “no material adverse effect” conditions that are broadly written and expressly include the absence of adverse market conditions, which if not satisfied in the discretion of the CLO arranger, entitle the arranger to determine not to proceed with the CLO.
    7. Arrangers and other banks that provide warehouse credit facilities (whether in anticipation of a CLO or as permanent financing) will usually retain full discretion to approve assets to be acquired under the warehouse facility. During adverse market conditions, the bank could use this discretion to cease approving assets.
    8. CLO managers that have warehouse credit facilities with market value default triggers or funding conditions might want to consider their options if a trigger is hit (e.g., make additional equity contributions, liquidate certain assets, or prepay the facility).

    There will be economic challenges posed by the coronavirus and the global response to it, and CLOs are likely to feel the effects. Schulte Roth & Zabel will continue to provide updates as further developments become known.

    Authored by Phillip J. Azzollini, Daniel V. Oshinsky, Craig Stein, James V. Williams, III and Vera Quagliato.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Phillip J. Azzollini

    Partner

    New York – 919 Third Avenue

    Daniel V. Oshinsky

    Partner

    New York – 919 Third Avenue

    Craig Stein

    Partner

    New York – 919 Third Avenue

    Vera Quagliato

    Partner

    New York – 919 Third Avenue

    More insights